Catalyst Brief

← Calendar

Readoutin 104d

AbbVie — Upadacitinib

Phase 3 primary completion: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus.

Date
Mar 2027
Type
Readout
Indication
Systemic Lupus Erythematosus

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from AbbVie

  1. Apr2027
  2. Mar2027
    Readoutin 104d
    AbbVie — Risankizumab SC
    Phase 3 primary completion: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease..
  3. Dec2026
  4. Dec2026
    Readoutin 14d
    AbbVie — Lutikizumab
    Phase 3 primary completion: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa.